Intestinal Toxicity Profile of PD-1 Inhibitor Combined with Platinum-Based Chemotherapy in a Lewis Lung Carcinoma Mouse Model

Abstract PD-1 inhibitor combined with platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer, but whether this combination exacerbates gastrointestinal toxicity remains unclear. In this descriptive study, we characterized the intestinal toxicity profile of PD-1 inhibitor and chemotherapy, alone and in combination, in a Lewis lung carcinoma mouse model. C57BL/6J mice bearing Lewis lung tumors were randomized into five groups (n = 8 per group): Control, Model, chemotherapy (carboplatin/pemetrexed), immunotherapy (anti-PD-1), and combination. Gastrointestinal toxicity was assessed by body weight, food and water intake, serum albumin and prealbumin, diarrhea score, disease activity index, colon length, and histopathological scoring. Intestinal barrier gene expression, mucosal immune parameters, inflammatory cytokine expression, and fecal short-chain fatty acids were measured. Combination therapy achieved superior antitumor efficacy compared with monotherapy (p < 0.05). Gastrointestinal toxicity in the combination group was comparable to chemotherapy alone (p > 0.05) but higher than in the Model and anti-PD-1 groups (p < 0.01). Chemotherapy was associated with reduced colonic occludin and claudin-1 mRNA expression (p < 0.05), and the addition of PD-1 inhibitor did not further alter this parameter. Foxp3 mRNA was lower in anti-PD-1-containing groups (p < 0.05). The anti-PD-1 group showed elevated colonic IFN-γ and reduced IL-10 mRNA (p < 0.05), with parallel changes in tumor tissues. Among short-chain fatty acids, isobutyrate was elevated in anti-PD-1-treated mice (p < 0.05), whereas other short-chain fatty acids showed no significant differences. These observations describe the differential intestinal toxicity profiles associated with chemotherapy and PD-1 inhibitor treatment and suggest associations that warrant further investigation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11093020/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Intestinal Toxicity Profile of PD-1 Inhibitor Combined with Platinum-Based Chemotherapy in a Lewis Lung Carcinoma Mouse Model

Li Dai, Fan-Lei Kong
Research Square
Cancer Immunotherapy and Biomarkers
preprint

Intestinal Toxicity Profile of PD-1 Inhibitor Combined with Platinum-Based Chemotherapy in a Lewis Lung Carcinoma Mouse Model

Li Dai, Fan-Lei Kong
preprint en

Abstract

Abstract PD-1 inhibitor combined with platinum-based chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer, but whether this combination exacerbates gastrointestinal toxicity remains unclear. In this descriptive study, we characterized the intestinal toxicity profile of PD-1 inhibitor and chemotherapy, alone and in combination, in a Lewis lung carcinoma mouse model. C57BL/6J mice bearing Lewis lung tumors were randomized into five groups (n = 8 per group): Control, Model, chemotherapy (carboplatin/pemetrexed), immunotherapy (anti-PD-1), and combination. Gastrointestinal toxicity was assessed by body weight, food and water intake, serum albumin and prealbumin, diarrhea score, disease activity index, colon length, and histopathological scoring. Intestinal barrier gene expression, mucosal immune parameters, inflammatory cytokine expression, and fecal short-chain fatty acids were measured. Combination therapy achieved superior antitumor efficacy compared with monotherapy (p < 0.05). Gastrointestinal toxicity in the combination group was comparable to chemotherapy alone (p > 0.05) but higher than in the Model and anti-PD-1 groups (p < 0.01). Chemotherapy was associated with reduced colonic occludin and claudin-1 mRNA expression (p < 0.05), and the addition of PD-1 inhibitor did not further alter this parameter. Foxp3 mRNA was lower in anti-PD-1-containing groups (p < 0.05). The anti-PD-1 group showed elevated colonic IFN-γ and reduced IL-10 mRNA (p < 0.05), with parallel changes in tumor tissues. Among short-chain fatty acids, isobutyrate was elevated in anti-PD-1-treated mice (p < 0.05), whereas other short-chain fatty acids showed no significant differences. These observations describe the differential intestinal toxicity profiles associated with chemotherapy and PD-1 inhibitor treatment and suggest associations that warrant further investigation.

Research Square
Shandong Provincial Hospital (CN), Qilu Hospital of Shandong University (CN)
Qilu Hospital of Shandong University, Natural Science Foundation of Shandong Province
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon